China Cognition and Aging Study
Launched by CAPITAL MEDICAL UNIVERSITY · Aug 29, 2018
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The China Cognition and Aging Study (China COAST) is a research project aimed at understanding dementia, including conditions like Mild Cognitive Impairment (MCI), Alzheimer’s Disease, and Vascular Dementia, among others. The study seeks to gather valuable information about how common these conditions are in China, what causes them, and how they can be diagnosed and treated. Researchers plan to collect data over several years from a wide range of participants, including healthy individuals and those with cognitive issues, to build a comprehensive database. This information will help improve the understanding and management of dementia in the future.
To participate, individuals must be at least 55 years old and provide consent. Those diagnosed with MCI or various forms of dementia, as well as healthy individuals, are welcome to join. Participants can expect to undergo assessments that may include tests of memory and thinking, brain scans, and blood samples. The study also aims to explore lifestyle factors that could help prevent dementia, as well as the emotional and social challenges faced by patients and their caregivers. Overall, this research is crucial for developing better strategies to combat cognitive disorders in China.
Gender
ALL
Eligibility criteria
- • Community population: age ≥ 55 years, male or female, with consent to participant the study.
- • Hospital population: subjects are all over 18 years old. Through clinical evaluation, neuropsychological test, imaging examination, blood and cerebrospinal fluid examination, etc, we will comprehensively evaluate the cognitive function and various test measures.
- • (1) MCI and its subtypes
- Inclusion criteria:
- • 1. Diagnosis according to 2004 Peterson's MCI criteria.
- • 2. CDR = 0.5.
- • 3. Memory loss is prominent, and may also be with other cognitive domain dysfunction.
- • 4. Insidious onset, slow progress.
- • 5. Not reaching the level of dementia.
- Exclusion criteria:
- • 1. With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral small vessal disease (Fazekas score ≥ 2 points).
- • 2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
- • 3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
- • 4. Mental and neurodevelopmental retardation.
- • 5. Contraindications to MRI.
- • 6. Suffering from a disease that cannot be combined with cognitive examination.
- • 7. Refuse to draw blood.
- • 8. Refuse to sign the informed consent at baseline
- • (2) Sporadic Alzheimer's disease (SAD)
- Inclusion criteria:
- • 1. Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.
- • 2. Subjects and their informed persons can complete relevant and follow- up examinations.
- • 3. Subjects or their authorized legal guardians sign the informed consent.
- Exclusion criteria:
- • 1. With a family history of dementia.
- • 2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
- • 3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
- • 4. Mental and neurodevelopmental retardation.
- • 5. Contraindications to MRI.
- • 6. Suffering from a disease that cannot be combined with cognitive examination.
- • 7. Refuse to draw blood.
- • 8. Refuse to sign the informed consent at baseline
- • (3) Familial Alzheimer's disease (FAD)
- Inclusion criteria:
- • 1. Written informed consent obtained from participant or legal guardian prior to any study-related procedures.
- • 2. Members in FAD pedigree (FAD is defined as at least two first- degree relatives suffer from AD).
- • 3. Aged 18 (inclusive) or older.
- • 4. At least two persons who can provide reliable information for the study. Note: Dementia is diagnosed according to the criteria described by DSM-IV-R. The diagnosis of AD is made using NINCDS-ADRDA or NIA-AA criteria. A diagnosis of MCI is assigned according to Petersen criteria.
- Exclusion criteria:
- • 1. Dementia caused by other factors such as depression, other psychiatric illnesses, thyroid dysfunction, encephalitis, multiple sclerosis, brain trauma, brain tumor, syphilis, acquired immunodeficiency syndrome (AIDS), Creutzfeldt-Jakob disease and other types of dementias such as vascular dementia (VaD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia (PDD).
- • 2. MRI and laboratory tests do not support or rule out a diagnosis of AD.
- • 3. Severe circulatory, respiratory, urinary, digestive, hematopoietic diseases (such as unstable angina, uncontrollable asthma, active gastric bleeding) and cancer.
- • 4. Participant has severe psychiatric illness or severe dementia that would interfere in completing initial and follow-up clinical assessments.
- • 5. With history of alcohol or drug abuse.
- • 6. Pregnant or lactating women.
- • 7. No reliable insiders.
- • 8. Refuse to sign the informed consent at baseline.
- • (4) Vascular dementia (VaD)
- Inclusion criteria:
- • Diagnosis for probable VaD according to NINDS-AIREN diagnostic criteria.
- MRI inclusion criteria:
- • All patients who meet clinical inclusion criteria should accept MRI scans which include an assessment of hippocampal volume.
- • 1. multiple (≥3) supratentorial subcortical small infarcts (3-20 mm in diameter) with or without any degree of white matter lesion (WML); or moderate to severe WML (Fazekas score ≥ 2), with or without small infarction; or ≥ 1 subcortical small infarct in key regions, such as caudate nucleus, globus pallidus, or thalamus.
- • 2. no cortical and watershed infarction, hemorrhage, hydrocephalus, or WML with specific causes (such as multiple sclerosis).
- • 3. no hippocampus or entorhinal cortex atrophy (MTA score = 0 point).
- Exclusion criteria:
- • 1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
- • 2. Other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
- • 3. With a history of mental illness or those with congenital mental retardation.
- • 4. Suffering from a disease that cannot be combined with a cognitive examination.
- • 5. Contraindications to MRI.
- • 6. Refuse to draw blood.
- • 7. Refuse to sign informed consent.
- • (5) Normal control
- Inclusion criteria:
- • 1. Aged 18 (inclusive) or above.
- • 2. Normal MMSE and MoCA evaluations. MMSE\>19 points for illiteracy, \>24 points for those educated less than 7 years, \>27 points for those educated equal to or more than 7 years. MoCA\>13 points for illiteracy, \>19 points for those educated less than 7 years, \>24 points for those educated equal to or more than 7 years.
- Exclusion criteria:
- • 1. Subjects with abnormal MMSE or MoCA scores.
- • 2. Subjects with a history of cerebral infarction, traumatic brain injury or related manifestations in MRI.
- • 3. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).
- • 4. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).
- • 5. Mental and neurodevelopmental retardation.
- • 6. Suffering from a disease that cannot be combined with a cognitive examination.
- • 7. Contraindications to MRI.
- • 8. Refuse to draw blood.
- • 9. Refuse to sign the informed consent at baseline.
About Capital Medical University
Capital Medical University is a leading institution in medical education and research, dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on scientific rigor and ethical standards, the university collaborates with a network of healthcare professionals and researchers to drive breakthroughs in medical science. Capital Medical University aims to enhance patient care and improve health outcomes by fostering a multidisciplinary approach to clinical research, ensuring that its trials are designed to address critical health challenges and contribute valuable insights to the medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Nanning, Guangxi, China
Jinan, Shandong, China
Wuhan, Hubei, China
Hefei, Anhui, China
Changchun, Jilin, China
Yinchuan, Ningxia, China
Hangzhou, Zhejiang, China
Hangzhou, Zhejiang, China
Qingdao, Shandong, China
Shenyang, Liaoning, China
Nanchang, Jiangxi, China
Dalian, Liaoning, China
Qingdao, Shandong, China
Guiyang, Guizhou, China
Taiyuan, Shanxi, China
Nanchong, Sichuan, China
Handan, Hebei, China
Changping, Beijing, China
Chaoyang, Beijing, China
Chaoyang, Beijing, China
Fengtai, Beijing, China
Haidian, Beijing, China
Haidian, Beijing, China
Haidian, Beijing, China
Xicheng, Beijing, China
Xicheng, Beijing, China
Yuzhong, Chongqing, China
Yuzhong, Chongqing, China
Fujian, Guangdong, China
Guangzhou, Guangdong, China
Zhongshan, Guangdong, China
Shijiazhuang, Hebei, China
Tangshan, Hebei, China
Zhijiazhuang, Hebei, China
Haerbin, Heilongjiang, China
Kaifeng, Henan, China
Zhengzhou, Henan, China
Wuhan, Hubei, China
Wuhan, Hunan, China
Wuhan, Hunan, China
Wuhan, Hunan, China
Nantong, Jiangsu, China
Subei, Jiangsu, China
Xuzhou, Jiangsu, China
Changchun, Jilin, China
Anshan, Liaoning, China
Dalian, Liaoning, China
Baotou, Nei Monggol, China
Yinchuan, Ningxia, China
Jining, Shandong, China
Qingdao, Shandong, China
Tai'an, Shandong, China
Huangpu, Shanghai, China
Luwan, Shanghai, China
Putong, Shanghai, China
Xi'an, Shanxi, China
Xi'an, Shanxi, China
Zigong, Sichuan, China
Heping, Tianjin, China
Jinnan, Tianjin, China
Urumqi, Xinjiang, China
Hangzhou, Zhejiang, China
Ningbo, Zhejiang, China
Wenzhou, Zhejiang, China
Patients applied
Trial Officials
Jianping Jia, Doctor
Study Chair
Xuanwu Hospital of Capital Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials